Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial

European Journal of Cancer

Volumn 48, Issue 5, 2012, Pages 721-727

  Gross Goupil, M ^a   Fourcade, A ^a   Blot, E ^b   Penel, N ^c   Negrier S ^d   Culine, S ^e   Chaigneau, L ^f   Lesimple, T ^g   Priou, F ^h   Lortholary, A ⁱ   Kaminsky, M C ^j   Provencal, J ^k   Voog, E ^l   Bouzy, J ^a   Laplanche, A ^a   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d CENTRE LÉON BÉRARD   (France)

^e CENTRE VAL D AURELLE   (France)

^f UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^g Centre Eugne Marquis   (France)

^h Centre Hospitalier General   (France)

ⁱ CENTRE PAUL PAPIN   (France)

^j CENTRE ALEXIS VAUTRIN   (France)

^k Centre Hospitalier de la Region d'Annecy   (France)

^l Clinique Victor Hugo   (France)

more..

Author keywords

Carcinoma of unknown primary; Chemotherapy; Cisplatin; Gemcitabine; Phase III trial

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ANEMIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; SURVIVAL RATE;

EID: 84858708576     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.011     Document Type: Article

References (31)

1. N. Pavlidis, and K. Fizazi Cancer of unknown primary (CUP) Crit Rev Oncol Hematol 54 2005 243 250 (Pubitemid 40693686)
2. E. Briasoulis, C. Tolis, J. Bergh, and N. Pavlidis ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP) Ann Oncol 16 Suppl. 1 2005 i75 i76
3. J.D. Hainsworth, and K. Fizazi Treatment for patients with unknown primary cancer and favorable prognostic factors Semin Oncol 36 2009 44 51
4. R. Lenzi, K.R. Hess, and M.C. Abbruzzese Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown primary carcinoma? J Clin Oncol 15 1997 2056 2062
5. S. Culine, A. Kramar, and M. Saghatchian Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of unknown primary site J Clin Oncol 20 2002 4679 4683 (Pubitemid 36025285)
6. J.R. Sporn, and B.R. Greenberg Empirical chemotherapy for adenocarcinoma of unknown primary tumor site Semin Oncol 20 1993 261 267 (Pubitemid 23171895)
7. N. Pavlidis, E. Briasoulis, and G. Pentheroudakis Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Supplement 5 2010 v228 v231
8. S. Culine, A. Lortholary, and J.J. Voigt Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary: results of a phase II study trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) J Clin Oncol 21 2003 3479 3482 (Pubitemid 46594080)
9. A. Trotti, R. Byhardt, and J. Stetz For the Radiation Therapy Oncology Group. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy Int J Radiat Oncol Biol Phys 47 2000 43 47
10. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines) J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
11. E.L. Kaplan, and P. Meier Non parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
12. K.J. Rothman Estimation of confidence limits for the cumulative probability of survival in life table analysis J Chronic Dis 31 1978 557 560 (Pubitemid 9027411)
13. K. Fizazi, and H.J. Schmoll Randomized trials in patients with carcinoma of an unknown primary site: the past, the present, and the future K. Fizazi, Carcinoma of an unknown primary site 2006 Taylor & Francis Books LLC 105 114
14. J.D. Hainsworth, D.R. Spigel, and B.L. Clark Paclitaxel/carboplatin/ etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial Cancer J 16 2010 70 75
15. M. Isik, M.M. Seker, H. Odabas, and F.T. Kos Gemcitabine and cisplatin in patients with carcinoma of unknown primary site Med Oncol 2010 doi: 10.1007/s12032-010-9465-8
16. K.B. Pittman, I.N. Olver, and B. Koczwara Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study Br J Cancer 95 2006 1309 1313 (Pubitemid 44760078)
17. D. Pouessel, S. Culine, and C. Becht Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site Cancer 100 2004 1257 1261 (Pubitemid 38325954)
18. A. Adenis, C. Ferté, and N. Penel Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis Invest New Drugs 28 2010 178 184
19. F.A. Greco, H.A. Burris 3rd, and S. Litchy Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study J Clin Oncol 20 2002 1651 1656 (Pubitemid 34260547)
20. H. Von der Maase, and L. Sengelov Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 21 2005 4602 4608 (Pubitemid 46224062)
21. J. Valle, H. Wasan, and D.H. Palmer Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 14 2010 1273 1281
22. T. Le Chevalier, G. Scagliotti, and R. Natale Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes Lung cancer 47 2005 69 80 (Pubitemid 39643243)
23. P. Busson, L. Daya-Grosjean, N. Pavlidis, and A. van de Wouw The biology of unknown primary tumors: the little we know, the importance of learning more K. Fizazi, Carcinoma of an unknown primary site 2006 Taylor & Francis Books LLC 159 171
24. J.D. Hainsworth, D.R. Spigel, and C. Farley Minnie Pearl Cancer Research Network. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network J Clin Oncol 25 2007 1747 1752 (Pubitemid 46797956)
25. C. Massard, J.J. Voigt, and A. Laplanche Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-kit tyrosine kinases potential targets for therapy? Br J Cancer 97 2007 857 861 (Pubitemid 47519298)
26. A.J. Van de Wouw, R.L. Jansen, and A.W. Griffiioen Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT Anticancer Res 24 2004 297 301 (Pubitemid 38279722)
27. J.D. Hainsworth, D.R. Spigel, and D.S. Thompson Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site Oncologist 14 2009 1189 1197
28. G.R. Varadhachary, D. Talantov, and M.N. Raber Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation J Clin Oncol 26 2008 4442 4448
29. J. Bridgewater, R. van Laar, A. Floore, and L. Van'T Veer Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary Br J Cancer 98 2008 1425 1430 (Pubitemid 351543580)
30. H.M. Horlings, R.K. van Laar, and J.M. Kerst Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary J Clin Oncol 26 2008 4435 4441
31. Gross-Goupil M, Loriot Y, Lesimple T et al. Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI.ECCO 15 - ESMO 34 [Abstr 1.331].